FDAnews
www.fdanews.com/articles/179407-spectranetics-wins-ce-mark-for-smaller-stellarex-dcb

Spectranetics Wins CE Mark for Smaller Stellarex DCB

November 22, 2016

Spectranetics has received CE Marking for its Stellarex 0.014 drug-coated angioplasty balloon (DCB).

The device is designed to treat small vessels, below-the-knee disease and critical limb ischemia in patients.

Stellarex is not available in the U.S. — Cynthia Jessup

View today's stories